EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy

Georgios X Papacharalampous, Jannis Constantinidis, George Fotiadis iD, Nan Zhang, Claus Bachert, Michael Katotomichelakis

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23234 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Georgios X Papacharalampous und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinosinusitis, Sinusitis, Biological Products. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The heterogeneity of existing studies, along with the fact that there are no published head‐to‐head trials, are the main reasons for the lack of guidelines regarding the selection of the proper biologic in treatment of chronic rhinosinusitis (CRS) with nasal polyps. The aim of this study is to summarize the current knowledge regarding the efficacy of omalizumab, dupilumab, and mepolizumab in CRS treatment. We also attempt to proceed to an indirect comparison of the agents and try to answer the tricky question: which agent to select and why?

Methods

An extensive search in English literature was conducted in PubMed/Medline, Embase, Google Scholar, and Cochrane Database/Library. Eligibility criteria included papers with full text published in English, adult population studies, clearly described intervention protocol, and documented primary and secondary outcomes.

Results

The studies included numbered 37. All agents provided significant improvement in polyp size, sinuses opacification, severity of symptoms, need for surgery and systemic corticosteroids use. Analysis of available systematic reviews, meta‐analyses and indirect treatment comparison studies showed that dupilumab appeared to be the most beneficial agent, in terms of primary and secondary outcomes. However, these results are of relatively low level of evidence due to several methodological limitations.

Conclusions

Although the present analysis showed a moderate supremacy of dupilumab, there is still no evidence‐based answer to the question “which biologic agent is the most effective in CRS treatment?” Improved statistical methodology, head‐to‐head trials, and real‐life studies could lead to more robust conclusions, establishing the real role of the specific biologic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsRhinosinusitisSinusitisBiological ProductsRhinitisAntibodies, Monoclonal, HumanizedAdultHumansOmalizumabChronic DiseaseQuality of Life

Stichwörter der Autor:innen

chronic rhinosinusitismedical therapy of chronic rhinosinusitisparanasal sinus disease

Substanzen

mepolizumabdupilumabOmalizumabBiological ProductsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
  • 1st Department of Otorhinolaryngology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Otorhinolaryngology - Head and Neck Surgery, University Hospital of Münster, Münster, Germany.
  • First Affiliated Hospital, Sun Yat-Sen University, International Airway Research Center, Guangzhou, China.
  • Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: George Fotiadis

Zitieren

APA

Papacharalampous, G. X., Constantinidis, J., Fotiadis, G., Zhang, N., Bachert, C., & Katotomichelakis, M. (2024). Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23234

Vancouver

Papacharalampous GX, Constantinidis J, Fotiadis G, Zhang N, Bachert C, Katotomichelakis M. Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23234

BibTeX
@article{Papacharalampous2024,
  author = {Papacharalampous, Georgios X and Constantinidis, Jannis and Fotiadis, George and Zhang, Nan and Bachert, Claus and Katotomichelakis, Michael},
  title = {Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23234}
}
Kostenlos starten →